Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia
Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks
In the register
The register attaches this trial to Minoxidil (topical), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Natalie GARCIA BARTELS
- Participants (registry)
- 70
- Start
- November 2010
- Primary completion
- March 2013
- Study completion
- March 2013
- Last registry update
- November 2013
- Countries
- Germany
Conditions studied: Androgenetic Alopecia
Interventions: Minoxidil, vehicle of 5% Minoxidil topical foam
Other trials of Minoxidil (topical)
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
- NCT07901426Active, not recruiting
Evaluation of the Scalp Skin Care Effects of Premium Revitalizing Elixir and Topical 5% Minoxidil
Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia
Efficacy & Safety of Minoxidil SL Tablets in Men With AGA
- NCT07056933Not yet recruiting
Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia
Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination in Male Androgenetic Alopecia
Treatment of Androgenetic Alopecia in Men for 24 Weeks
Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.